- Home
- MDIA vs SKYE Comparison
MDIA vs SKYE Comparison
Compare MDIA & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDIA | SKYE |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 44.9M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MDIA | SKYE |
|---|---|---|
| Price | $0.61 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 30.3K | ★ 233.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 80.00 | ★ 86.41 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,571,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.05 | N/A |
| 52 Week Low | $0.54 | $0.68 |
| 52 Week High | $1.60 | $5.75 |
Technical Indicators
Market Signals| Indicator | MDIA | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 40.60 |
| Support Level | $0.56 | $0.68 |
| Resistance Level | $0.65 | $0.83 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 78.96 | 34.30 |
Price Performance
Historical ComparisonAbout MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.